Which has grown faster, ASTH or NVAX?

Over the past five years, NVAX grew revenue faster — ASTH at a 53.77% CAGR versus NVAX at 118.86%.

Is ASTH or NVAX more profitable?

ASTH runs the higher net margin — ASTH at 1.05% versus NVAX at -59.87%.

How have ASTH and NVAX total returns compared?

Over the past 10 years, ASTH delivered 25.17% and NVAX delivered -10.98% annualized total return. Past performance doesn't predict future results.

Astrana Health, Inc. (ASTH) vs Novavax, Inc. (NVAX)

A side-by-side comparison of Astrana Health, Inc. and Novavax, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ASTH

Astrana Health, Inc.

$1.84B

$37.03HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT

NVAX

Novavax, Inc.

$1.87B

$11.36HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT

Total return — ASTH vs NVAX

growth of $100 · dividends reinvested · last 10y

ASTH +820.3% (+24.9%/yr)NVAX -68.6% (-10.9%/yr)ASTH compounded faster over this window

Log scale — wide-divergence pair

ASTH NVAX

ASTH vs NVAX: by the numbers

•NVAX is the larger company ($1.87B vs $1.84B market cap).
•ASTH is profitable (1.05% net margin) while NVAX runs a net loss (-59.87%).
•NVAX grew revenue faster over the past five years (118.86% vs 53.77% CAGR).

Metrics side by side

Valuation

Metric	ASTH	NVAX
P/E ratio	45.30	N/A
Forward P/E	26.49	N/A
P/S ratio	0.48	4.51
P/B ratio	2.21	N/A
EV / EBITDA	13.49	N/A
FCF yield	8.63%	N/A

Profitability

Metric	ASTH	NVAX
Gross margin	9.22%	93.67%
Operating margin	2.61%	50.14%
Net margin	1.05%	-59.87%
ROE	4.88%	N/A
ROIC	4.13%	-36.37%

Growth (annualized)

Metric	ASTH	NVAX
Revenue CAGR (5Y)	53.77%	118.86%
EPS CAGR (5Y)	-15.06%	N/A
FCF CAGR (5Y)	18.35%	N/A
Total return CAGR (5Y)	-16.52%	-40.61%

Frequently asked

Which has grown faster, ASTH or NVAX?: Over the past five years, NVAX grew revenue faster — ASTH at a 53.77% CAGR versus NVAX at 118.86%.
Is ASTH or NVAX more profitable?: ASTH runs the higher net margin — ASTH at 1.05% versus NVAX at -59.87%.
How have ASTH and NVAX total returns compared?: Over the past 10 years, ASTH delivered 25.17% and NVAX delivered -10.98% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ASTH analysis Full NVAX analysis Interactive comparison tool

Dig into the metrics

Astrana Health P/E ratio Astrana Health ROE Novavax ROE Astrana Health operating margin Novavax operating margin Astrana Health revenue growth Novavax revenue growth Astrana Health free cash flow Novavax free cash flow

Astrana Health & Novavax appear in these rankings

Fastest Revenue Growth Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.